Windward Bio to Participate at the Jefferies London Global Healthcare Conference

November 17, 2026

BASEL, Switzerland, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG ("Windward") (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced that members of management will present at the Jefferies London Global Healthcare Conference on Wednesday, November 18, 2026, at 8:30 a.m.GMT.

A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Windward Bio website.

About Windward Bio Group AG

Windward (Nasdaq: WWB) is a global, clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead product candidate, WIN378, is a fully human monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and is being evaluated in the POLARIS-1 Phase 2/3 study in severe uncontrolled asthma and the SIRIUS Phase 2 study in COPD. Windward's second product candidate, WIN027, is an ultra-long-acting bispecific antibody targeting TSLP and interleukin-13 (IL-13) and is currently in a Phase 1 healthy volunteer study.

For media and investor inquiries:
Noel Kurdi
SVP, Investor Relations and Communications
Windward Bio
investors@windwardbio.com